The document discusses the regulatory requirements for approval of various drugs and therapies in the United States. It covers the approval process for active pharmaceutical ingredients (APIs), biologics, novel drugs, and new drug applications (NDAs). APIs must be approved through a Drug Master File (DMF) submitted to the FDA, which provides confidential details about manufacturing. Biologics and blood products require registration with the FDA. Novel drugs undergo clinical trials to demonstrate safety and efficacy. The FDA aims to expedite approval of breakthrough therapies through pathways like Fast Track, Breakthrough Therapy Designation, Accelerated Approval, and Priority Review.
This presentation is regarding the rules in hipaa that are implemented by HHS followed by information regarding PHI(protected health information) and MNS(minimum necessary standards)in hipaa ; and how hipaa regulations followed during clinical trials
This document discusses bioequivalence studies. It begins with an introduction and objectives. It then defines bioequivalence according to the FDA and WHO as the rates and extents of active ingredients being available between two products. It discusses the need for bioequivalence studies for generic approval and reasons for in vivo studies. It also covers study designs, types of evidence to establish bioequivalence, statistical evaluation of data, and biowaivers. The overall purpose is to ensure generic drugs are equivalent to their brand name counterparts in performance.
This document provides an overview of Abbreviated New Drug Applications (ANDAs) in 3 sentences or less:
The document introduces ANDAs as applications submitted to FDA to review and approve generic drug products once approved, allowing manufacturers to market safe and effective low-cost alternatives, and discusses various topics related to ANDA guidelines, requirements, review process, and regulations. It is dedicated to the author's son and aims to provide information to both academia and industry through free websites and articles to support millions of readers.
An ANDA contains data submitted to the FDA to review and approve a generic drug product. Once approved, a generic manufacturer can produce and market a safe, low-cost alternative to the innovator drug. All approved drugs are listed in the Orange Book. ANDAs have four types of submissions: Paragraph I for drugs with no listed patents allowing immediate approval; Paragraph II for off-patent drugs; Paragraph III where generics agree not to market until patents expire; and Paragraph IV for generics believing patents are invalid allowing earlier market entry. The examples show drugs with Paragraph III certifications and their patent expiration dates.
The document discusses Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Abbreviated New Drug Applications (ANDAs). It provides information on the purpose and requirements for submitting each type of application to regulatory agencies like the FDA.
An IND is required to get approval to conduct clinical trials of an investigational drug in humans. It must contain preclinical and manufacturing data as well as details on the proposed clinical trial protocol. An NDA is submitted to seek marketing approval for a new drug after Phase III trials. It contains extensive data from nonclinical studies, clinical trials, and information on manufacturing. An ANDA can be submitted for a generic drug to demonstrate equivalence to an approved brand name
This document summarizes the Hatch-Waxman Act, which established the modern system for regulating generic drugs in the US. The Act aims to make generic drugs more accessible by streamlining the approval process for generics while also providing incentives to brand name drug companies. It allows generics to challenge drug patents and grants exclusivity periods to first generic applicants and brand name drugs for new chemical entities. The Orange Book lists approved drug products and related patent information.
An Investigational New Drug Application (IND) is a request from a clinical study sponsor to obtain authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans.
An Investigator IND is submitted by a physician who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed. A physician might submit a research IND to propose studying an unapproved drug, or an approved product for a new indication or in a new patient population.
This presentation is regarding the rules in hipaa that are implemented by HHS followed by information regarding PHI(protected health information) and MNS(minimum necessary standards)in hipaa ; and how hipaa regulations followed during clinical trials
This document discusses bioequivalence studies. It begins with an introduction and objectives. It then defines bioequivalence according to the FDA and WHO as the rates and extents of active ingredients being available between two products. It discusses the need for bioequivalence studies for generic approval and reasons for in vivo studies. It also covers study designs, types of evidence to establish bioequivalence, statistical evaluation of data, and biowaivers. The overall purpose is to ensure generic drugs are equivalent to their brand name counterparts in performance.
This document provides an overview of Abbreviated New Drug Applications (ANDAs) in 3 sentences or less:
The document introduces ANDAs as applications submitted to FDA to review and approve generic drug products once approved, allowing manufacturers to market safe and effective low-cost alternatives, and discusses various topics related to ANDA guidelines, requirements, review process, and regulations. It is dedicated to the author's son and aims to provide information to both academia and industry through free websites and articles to support millions of readers.
An ANDA contains data submitted to the FDA to review and approve a generic drug product. Once approved, a generic manufacturer can produce and market a safe, low-cost alternative to the innovator drug. All approved drugs are listed in the Orange Book. ANDAs have four types of submissions: Paragraph I for drugs with no listed patents allowing immediate approval; Paragraph II for off-patent drugs; Paragraph III where generics agree not to market until patents expire; and Paragraph IV for generics believing patents are invalid allowing earlier market entry. The examples show drugs with Paragraph III certifications and their patent expiration dates.
The document discusses Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Abbreviated New Drug Applications (ANDAs). It provides information on the purpose and requirements for submitting each type of application to regulatory agencies like the FDA.
An IND is required to get approval to conduct clinical trials of an investigational drug in humans. It must contain preclinical and manufacturing data as well as details on the proposed clinical trial protocol. An NDA is submitted to seek marketing approval for a new drug after Phase III trials. It contains extensive data from nonclinical studies, clinical trials, and information on manufacturing. An ANDA can be submitted for a generic drug to demonstrate equivalence to an approved brand name
This document summarizes the Hatch-Waxman Act, which established the modern system for regulating generic drugs in the US. The Act aims to make generic drugs more accessible by streamlining the approval process for generics while also providing incentives to brand name drug companies. It allows generics to challenge drug patents and grants exclusivity periods to first generic applicants and brand name drugs for new chemical entities. The Orange Book lists approved drug products and related patent information.
An Investigational New Drug Application (IND) is a request from a clinical study sponsor to obtain authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans.
An Investigator IND is submitted by a physician who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed. A physician might submit a research IND to propose studying an unapproved drug, or an approved product for a new indication or in a new patient population.
The document discusses drug product performance evaluation through in vitro dissolution testing. It provides details on factors that influence drug dissolution like drug substance properties, formulation composition, manufacturing process, and dissolution test conditions. The key goals of in vitro drug product testing are to characterize drug potency and release rate from oral dosage forms, provide information for formulation development, and ensure quality, comparability and stability over time. Common tests include disintegration testing and dissolution testing using apparatus specified in pharmacopeias to simulate gastrointestinal conditions. The results of in vitro testing aid product development and assessment of shelf-life and quality.
NDA and ANDA regulatory approval processNilesh Gawade
This document discusses the regulatory approval processes for new drug applications (NDAs) and abbreviated new drug applications (ANDAs) in the United States. It explains that an NDA contains extensive clinical and non-clinical data submitted by an innovator company to obtain approval for a new drug. An ANDA contains similar data to demonstrate equivalence to an already approved drug for generic versions after patents have expired. The document provides details on the requirements, review processes, and certification pathways for both NDAs and ANDAs.
The document discusses the roles and responsibilities of chemistry, manufacturing, and controls (CMC) regulatory affairs professionals. CMC ensures that pharmaceutical products are manufactured according to good manufacturing practices and that facilities meet regulatory standards. CMC regulatory affairs professionals work with various teams to provide CMC strategy, submit required information to regulatory agencies for approvals, and make submissions for any post-approval changes or studies. They act as responsible agents and certify that submissions meet all requirements.
This document discusses post-marketing surveillance (PMS), which involves monitoring the safety of pharmaceutical drugs and medical devices after they have been approved and released on the market. PMS is important because pre-approval clinical trials involve limited numbers of patients and cannot detect all potential adverse effects. The document outlines the history of PMS, sources of PMS information, benefits of PMS systems, methods of surveillance including spontaneous reporting and cohort studies, and how manufacturers can establish PMS procedures and systems to gather feedback on their products.
Clinical trials First Year M. Pharmacy.Rushi Somani
The document discusses three topics:
1) Institutional Review Boards, which protect the rights and welfare of clinical trial subjects. IRBs review and approve research protocols.
2) HIPAA, which establishes standards to protect private health information. It covers entities like health plans and providers.
3) Pharmacovigilance, which monitors the safety of medicines. It aims to identify new hazards and improve patient outcomes. Adverse drug reactions and side effects are reported to monitoring programs.
This document provides an overview of the drug approval processes in the United States, Europe, and India. In the US, drugs must undergo investigational new drug application and new drug application processes with the FDA, including clinical trials and demonstrating safety and efficacy. Europe has a centralized process through the EMA for certain drugs and mutual recognition or national processes for others. India requires new drugs to conduct clinical trials and submit a new drug application to the DCGI to prove safety and effectiveness in the Indian population. While requirements vary between regions, the overall goals are to safeguard public health by ensuring pharmaceutical quality, safety and efficacy.
Abbreviated New Drug Application [ANDA]Sagar Savale
An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product.
I. INTRODUCTION
II. DEFINITIONS
III. TYPES OF DRUG MASTER FILES
IV. SUBMISSIONS TO DRUG MASTER FILES
V. AUTHORIZATION TO REFER TO A DRUG MASTER FILE
VI. PROCESSING AND REVIEWING POLICIES
VII. HOLDER OBLIGATIONS
IX. CLOSURE OF A DRUG MASTER FILE.
This document provides an overview of preformulation studies for drug development. It discusses the importance of characterizing key physicochemical properties of drug substances such as solubility, ionization constants, melting point, and polymorphism. It also covers the role of excipients and how drug-excipient interactions can impact stability. The document concludes with sections on stability studies, factors that influence stability, and guidelines for stability testing procedures and frequencies.
The document discusses the Common Technical Document (CTD) format, which was created by the International Conference on Harmonisation to standardize the submission of documentation for drug approval across regions. It provides a five-module structure for organizing quality, safety, efficacy and other information. While CTD helped streamline submissions, the electronic CTD (eCTD) was later developed to further facilitate electronic transfer and review of documentation between regulators and industry. eCTD utilizes XML formatting and allows lifecycle management of submissions but implementation presents challenges around file formats, regional rules and last minute changes.
it provide a brief note on the drug excipient interaction and various technique to find it which is a part of preformulation studies. it gives help to mpharm(pharmaceutics) students. i.
The document discusses the regulatory requirements for approval of APIs, biologics, novel drugs, and NDAs. It covers topics such as:
- APIs must be approved through a Drug Master File (DMF) in the US or Active Substance Master File (ASMF) in Europe. A DMF contains confidential manufacturing and quality information for review.
- Biological products like blood components require registration with the FDA and annual listing of manufactured products.
- Approval of novel drugs involves analyzing the medical need and risks/benefits based on clinical trial data, with strategies to manage identified risks.
- The FDA uses various pathways like Fast Track, Breakthrough Therapy, and Accelerated Approval to
This document provides a summary of a presentation on generic drugs. It discusses the definition of generic drugs, the generic drug development and approval process, provisions of the Hatch-Waxman Act, and relevant sections of the Code of Federal Regulations. The summary highlights that a generic drug must be equivalent to the branded version in ingredients, dosage, safety and efficacy. It also outlines the steps in generic drug approval via an Abbreviated New Drug Application, including requirements for bioequivalence testing and patent certifications. Additionally, it notes provisions established by the Hatch-Waxman Act related to patent term extensions and patent challenges involved in the generic approval pathway.
Validation (intro, scope, merits, ich, who guidelines)PRAJAKTASAWANT33
This document summarizes a presentation on validation given by Prajakta Sawant, a first year M.Pharm student at Alard College of Pharmacy in Pune, India. The presentation covered the need for validation, types of validation including process, cleaning, equipment and analytical method validation. It discussed validation concepts such as the validation master plan, documentation, and ICH and WHO guidelines. The goal of validation is to ensure consistent production of pharmaceuticals meeting quality standards.
cmc [ chemistry manufacturing control ]Akshay Patil
This document provides information about Chemistry, Manufacturing and Controls (CMC) regulatory affairs. It discusses the responsibilities of CMC regulatory affairs in providing leadership, strategy and regulatory knowledge to achieve approval of pharmaceutical products. It also summarizes key elements included in CMC regulatory submissions like manufacturing sites, analytical methods and quality testing data. The document further discusses post-approval regulatory requirements including post-approval studies and safety surveillance. It provides examples of combination products and medical device regulations. It introduces the Common Technical Document (CTD) format for registration applications and its electronic version (eCTD). Finally, it summarizes some key ICH guidelines.
Regulatory requirement for approval of BiologicsArpitha Aarushi
The document is a presentation on regulatory requirements for approval of biologics submitted by Arpitha B. M. to Dr. D. Manjula. It contains an introduction, history of biologics regulation citing key events, sources and types of biologics, differences between biologics and chemical drugs, the regulatory approval process including biological license application, and references. The presentation provides an overview of biologics, their regulation and approval process in India.
The document provides information about the New Drug Application (NDA) process. The NDA is submitted to the FDA to obtain approval for a new pharmaceutical. It contains clinical and non-clinical data, chemistry information, and manufacturing details. The NDA follows guidelines for formatting and submission. It includes an archival copy that contains all sections and a review copy divided into technical sections bound with colored covers. The document outlines the contents and organization required for each section of the NDA.
Welcome to our informative slide on the New Drug Application (NDA) - a pivotal milestone in the pharmaceutical world that propels medical innovation to new heights. In this concise presentation, we'll explore the significance of the NDA process and its critical role in bringing life-changing medications to patients in need.
The document discusses drug product performance evaluation through in vitro dissolution testing. It provides details on factors that influence drug dissolution like drug substance properties, formulation composition, manufacturing process, and dissolution test conditions. The key goals of in vitro drug product testing are to characterize drug potency and release rate from oral dosage forms, provide information for formulation development, and ensure quality, comparability and stability over time. Common tests include disintegration testing and dissolution testing using apparatus specified in pharmacopeias to simulate gastrointestinal conditions. The results of in vitro testing aid product development and assessment of shelf-life and quality.
NDA and ANDA regulatory approval processNilesh Gawade
This document discusses the regulatory approval processes for new drug applications (NDAs) and abbreviated new drug applications (ANDAs) in the United States. It explains that an NDA contains extensive clinical and non-clinical data submitted by an innovator company to obtain approval for a new drug. An ANDA contains similar data to demonstrate equivalence to an already approved drug for generic versions after patents have expired. The document provides details on the requirements, review processes, and certification pathways for both NDAs and ANDAs.
The document discusses the roles and responsibilities of chemistry, manufacturing, and controls (CMC) regulatory affairs professionals. CMC ensures that pharmaceutical products are manufactured according to good manufacturing practices and that facilities meet regulatory standards. CMC regulatory affairs professionals work with various teams to provide CMC strategy, submit required information to regulatory agencies for approvals, and make submissions for any post-approval changes or studies. They act as responsible agents and certify that submissions meet all requirements.
This document discusses post-marketing surveillance (PMS), which involves monitoring the safety of pharmaceutical drugs and medical devices after they have been approved and released on the market. PMS is important because pre-approval clinical trials involve limited numbers of patients and cannot detect all potential adverse effects. The document outlines the history of PMS, sources of PMS information, benefits of PMS systems, methods of surveillance including spontaneous reporting and cohort studies, and how manufacturers can establish PMS procedures and systems to gather feedback on their products.
Clinical trials First Year M. Pharmacy.Rushi Somani
The document discusses three topics:
1) Institutional Review Boards, which protect the rights and welfare of clinical trial subjects. IRBs review and approve research protocols.
2) HIPAA, which establishes standards to protect private health information. It covers entities like health plans and providers.
3) Pharmacovigilance, which monitors the safety of medicines. It aims to identify new hazards and improve patient outcomes. Adverse drug reactions and side effects are reported to monitoring programs.
This document provides an overview of the drug approval processes in the United States, Europe, and India. In the US, drugs must undergo investigational new drug application and new drug application processes with the FDA, including clinical trials and demonstrating safety and efficacy. Europe has a centralized process through the EMA for certain drugs and mutual recognition or national processes for others. India requires new drugs to conduct clinical trials and submit a new drug application to the DCGI to prove safety and effectiveness in the Indian population. While requirements vary between regions, the overall goals are to safeguard public health by ensuring pharmaceutical quality, safety and efficacy.
Abbreviated New Drug Application [ANDA]Sagar Savale
An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product.
I. INTRODUCTION
II. DEFINITIONS
III. TYPES OF DRUG MASTER FILES
IV. SUBMISSIONS TO DRUG MASTER FILES
V. AUTHORIZATION TO REFER TO A DRUG MASTER FILE
VI. PROCESSING AND REVIEWING POLICIES
VII. HOLDER OBLIGATIONS
IX. CLOSURE OF A DRUG MASTER FILE.
This document provides an overview of preformulation studies for drug development. It discusses the importance of characterizing key physicochemical properties of drug substances such as solubility, ionization constants, melting point, and polymorphism. It also covers the role of excipients and how drug-excipient interactions can impact stability. The document concludes with sections on stability studies, factors that influence stability, and guidelines for stability testing procedures and frequencies.
The document discusses the Common Technical Document (CTD) format, which was created by the International Conference on Harmonisation to standardize the submission of documentation for drug approval across regions. It provides a five-module structure for organizing quality, safety, efficacy and other information. While CTD helped streamline submissions, the electronic CTD (eCTD) was later developed to further facilitate electronic transfer and review of documentation between regulators and industry. eCTD utilizes XML formatting and allows lifecycle management of submissions but implementation presents challenges around file formats, regional rules and last minute changes.
it provide a brief note on the drug excipient interaction and various technique to find it which is a part of preformulation studies. it gives help to mpharm(pharmaceutics) students. i.
The document discusses the regulatory requirements for approval of APIs, biologics, novel drugs, and NDAs. It covers topics such as:
- APIs must be approved through a Drug Master File (DMF) in the US or Active Substance Master File (ASMF) in Europe. A DMF contains confidential manufacturing and quality information for review.
- Biological products like blood components require registration with the FDA and annual listing of manufactured products.
- Approval of novel drugs involves analyzing the medical need and risks/benefits based on clinical trial data, with strategies to manage identified risks.
- The FDA uses various pathways like Fast Track, Breakthrough Therapy, and Accelerated Approval to
This document provides a summary of a presentation on generic drugs. It discusses the definition of generic drugs, the generic drug development and approval process, provisions of the Hatch-Waxman Act, and relevant sections of the Code of Federal Regulations. The summary highlights that a generic drug must be equivalent to the branded version in ingredients, dosage, safety and efficacy. It also outlines the steps in generic drug approval via an Abbreviated New Drug Application, including requirements for bioequivalence testing and patent certifications. Additionally, it notes provisions established by the Hatch-Waxman Act related to patent term extensions and patent challenges involved in the generic approval pathway.
Validation (intro, scope, merits, ich, who guidelines)PRAJAKTASAWANT33
This document summarizes a presentation on validation given by Prajakta Sawant, a first year M.Pharm student at Alard College of Pharmacy in Pune, India. The presentation covered the need for validation, types of validation including process, cleaning, equipment and analytical method validation. It discussed validation concepts such as the validation master plan, documentation, and ICH and WHO guidelines. The goal of validation is to ensure consistent production of pharmaceuticals meeting quality standards.
cmc [ chemistry manufacturing control ]Akshay Patil
This document provides information about Chemistry, Manufacturing and Controls (CMC) regulatory affairs. It discusses the responsibilities of CMC regulatory affairs in providing leadership, strategy and regulatory knowledge to achieve approval of pharmaceutical products. It also summarizes key elements included in CMC regulatory submissions like manufacturing sites, analytical methods and quality testing data. The document further discusses post-approval regulatory requirements including post-approval studies and safety surveillance. It provides examples of combination products and medical device regulations. It introduces the Common Technical Document (CTD) format for registration applications and its electronic version (eCTD). Finally, it summarizes some key ICH guidelines.
Regulatory requirement for approval of BiologicsArpitha Aarushi
The document is a presentation on regulatory requirements for approval of biologics submitted by Arpitha B. M. to Dr. D. Manjula. It contains an introduction, history of biologics regulation citing key events, sources and types of biologics, differences between biologics and chemical drugs, the regulatory approval process including biological license application, and references. The presentation provides an overview of biologics, their regulation and approval process in India.
The document provides information about the New Drug Application (NDA) process. The NDA is submitted to the FDA to obtain approval for a new pharmaceutical. It contains clinical and non-clinical data, chemistry information, and manufacturing details. The NDA follows guidelines for formatting and submission. It includes an archival copy that contains all sections and a review copy divided into technical sections bound with colored covers. The document outlines the contents and organization required for each section of the NDA.
Welcome to our informative slide on the New Drug Application (NDA) - a pivotal milestone in the pharmaceutical world that propels medical innovation to new heights. In this concise presentation, we'll explore the significance of the NDA process and its critical role in bringing life-changing medications to patients in need.
Regulatory requirements for drug approval .pptxAanchalDevi
The document discusses regulatory requirements for approval of novel drug therapies. Novel drugs are innovative products that address previously unmet medical needs. In the US, the FDA's CDER approves new drugs and biological products annually, including new molecular entities. Approval pathways aim to expedite development and review of drugs that treat serious conditions. Faster pathways like Fast Track, Breakthrough Therapy and Priority Review enable more interaction with developers and shortened review timelines. Rules for approval assess benefits, risks from clinical data, and strategies for managing risks.
This document provides an overview of the New Drug Application (NDA) process. It discusses what an NDA is, its goals, forms, contents, guidance documents, submission process, and review/approval. Key points include that an NDA is required for marketing approval of new drugs in the US and contains data from clinical trials demonstrating safety and effectiveness. The review process evaluates these factors and can result in approval or refusal. Guidance documents provide guidelines for preparing and submitting the various sections of an NDA to the FDA.
The document discusses Investigational New Drug Applications (INDs), New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), and Supplemental New Drug Applications (SNDAs). It provides details on the purpose and requirements of each application type, including necessary contents, guidelines, and the laws and regulations that govern the FDA drug approval process.
The document provides an overview of the requirements for a New Drug Application (NDA) submitted to the FDA for approval of a new pharmaceutical. An NDA must include extensive information on clinical trials demonstrating safety and efficacy, chemistry and manufacturing, and product labeling. It follows studies conducted under an Investigational New Drug application and provides all relevant data to allow the FDA to determine if the drug is safe, effective and manufactured properly. The review process involves evaluation by experts in areas like clinical research, chemistry and statistics. Guidance documents provide detailed requirements for the format and content of each section of an NDA.
Application for New Drug Discovery (NDD) according to USFDA guidelines Bharathiar university
The document discusses the US FDA's process for approving new drug applications (NDAs). The FDA is responsible for ensuring drugs are safe, effective and quality-controlled. Developers must submit clinical data to FDA's Center for Drug Evaluation and Research which reviews the data. If benefits outweigh risks, the drug receives approval. For serious conditions, accelerated approval is possible where post-market studies confirm initial findings. Designations like Fast Track can expedite review of innovative drugs that address unmet needs. A complete NDA includes manufacturing and clinical information. Advisory committees provide recommendations to FDA on approval.
The document discusses various stages of drug discovery and development. It begins with an introduction to traditional methods of drug discovery and advances in understanding disease at the molecular level. It then covers key stages like drug discovery, preclinical studies, clinical trials, and regulatory approvals required by agencies like the FDA and India's CDSCO. Different types of applications submitted during development and regulatory processes are explained, including IND, NDA, ANDA, SNDA, and supplements for post-approval changes. Challenges and methods in each stage are also summarized.
An abbreviated new drug application (ANDA) contains data submitted to the FDA for review and potential approval of a generic drug product. Once approved, an ANDA allows a company to manufacture and market a generic drug as a lower-cost alternative to the brand-name drug. A new drug application (NDA) is required for all new drugs and provides data to allow the FDA to determine if a drug is safe and effective for its intended use. Both ANDAs and NDAs must demonstrate appropriate manufacturing controls and quality. Guidance documents provide guidelines for submitting ANDAs and NDAs to the FDA for review.
This document provides an overview of regulatory requirements for drugs and pharmaceuticals. It discusses drug regulation by international agreements and regulatory authorities like the FDA. The FDA is organized into centers responsible for drugs, biologics, devices and food. Applications like IND, NDA, ANDA are described which are required for investigational and approved drugs. The new drug approval process is outlined involving pre-clinical and clinical testing taking 10+ years. Key differences between NDA for new drugs and ANDA for generic drugs are summarized.
MRA201 T. Unit 1 Regulatory aspects of drugs and cosmetics unit 1.pptxDimple Marathe
organization, structure, function of FDA, FR, CFR, FFDCA, Approval process of IND, NDA, ANDA, orphan drug, combination product, changes to approved NDA, ANDA, packaging labelling of pharmaceutical.
Investigational new drug application must be submitted after discovering a new drug and before beginning of clinical trials. Here given a brief note on the topic.The topics included are types of IND, criteria for application, Information in IND application, resources for IND application, laws.regulations, policies and procedures, IND forms and instructions, IND content requirements and review of IND
The document discusses the process for submitting a New Drug Application (NDA) to the FDA for approval of a new pharmaceutical. It explains that an NDA contains extensive information on the drug's safety and efficacy established during clinical trials. The FDA assembles review teams to evaluate the NDA across several technical sections including chemistry, non-clinical studies, clinical data, and labeling. The review process involves determining if the application is complete and classifying it for either priority or standard review, with priority given to drugs that would significantly improve treatment options.
NDA and ANDA regulatory approval processJagrutiKale1
This document provides an overview of New Drug Applications (NDA) and Abbreviated New Drug Applications (ANDA). It discusses the requirements and process for submitting both full NDAs for new drugs and ANDAs for generic drugs. The key aspects covered are the format and content of NDA submissions, the review process by the FDA, and the different types of approval letters. It also explains the goals and requirements of the ANDA pathway for generic drugs established by the Hatch-Waxman Act, including the necessary patent certifications and the review process.
The document discusses New Drug Applications (NDAs) submitted to the FDA for approval of new drug products. It describes how NDAs contain data from animal and human clinical trials demonstrating a drug's safety and effectiveness. There are different types of NDAs depending on if a drug is novel or similar to existing drugs. The FDA reviews NDAs to determine if manufacturing is adequate and if a drug's benefits outweigh its risks based on the application contents and recommendations are made for approval or further work required. Approved drugs require ongoing safety monitoring and reporting to the FDA.
It includes information about regulatory bodies, role of drug Regulatory professional, countries with their regulatory bodies, intellectual property rights, terminologies related to DRA, drug approval process, event regarding lack of Drug regulatory affairs
The document discusses international drug regulatory affairs. It provides an overview of the regulatory structures and agencies that govern the pharmaceutical industry. The key regulatory bodies discussed include the FDA in the US, EMEA in Europe, and other agencies in countries like Japan, Australia, Brazil, Nigeria, China, and India. The document also summarizes the various approval processes for new drugs and generics, including requirements for clinical trials, applications, and common technical dossier formats. Common challenges in international regulatory approval are also briefly mentioned.
The document summarizes several regulatory agencies that regulate pharmaceutical products around the world. It discusses the roles and functions of the CDSCO in India, FDA in the United States, TGA in Australia, Health Canada, and MHRA in the UK. For each agency, it provides information on their goals, activities related to drug approval and regulation, and key application forms.
The document discusses the Abbreviated New Drug Application (ANDA) process overseen by the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER). It describes the requirements for an ANDA, including establishing bioequivalence to the reference listed drug through bioequivalence studies, and certifying patent status. Upon receiving an ANDA, the CDER determines if the application is complete and acceptable for review. If approved, generic drugs must demonstrate equivalence to the reference drug in dosage form, strength, quality and performance.
The document discusses the regulatory process for investigational new drugs (INDs) and new drug applications (NDAs) in the United States. It provides details on the types of INDs (investigator, emergency use, treatment), categories (commercial, research), required contents of an IND application, and FDA's Pre-IND consultation program. It also summarizes the purpose and required contents of an NDA to obtain approval to market a new drug in the US. Laws, regulations, guidance documents, and procedures that FDA follows in regulating drugs are also referenced.
Similar to apibiologicsnoveltherapies-220521094211-c5976336.pptx (20)
The document discusses quality by design (QbD) in pharmaceutical development. It defines QbD and describes its objectives to achieve quality products through a systematic approach involving predefined targets and process understanding. The key aspects of QbD include defining target product and quality profiles, identifying critical quality attributes and material/process parameters through risk assessment, establishing a design space, and implementing a control strategy with life cycle management. Various tools used in QbD such as design of experiments are also outlined.
Computers have played an increasingly important role in pharmaceutical research and development since the 1960s. In the 1960s, computational chemistry was still primarily conducted in academia. Programs were shared through repositories like the Quantum Chemistry Program Exchange. In the 1970s, pharmaceutical companies like Lilly and Merck began adopting computational techniques. The 1980s saw further growth with advances in computing power from technologies like mainframe computers and personal computers. Statistical modeling and optimization techniques became more widely used in the 1990s to aid drug discovery and development. Population modeling also emerged as a tool to understand variability in drug exposure and response.
This document discusses the physics and process of tablet compression. It defines compression as the reduction of bulk volume by removing air through applied pressure. Compaction is compression combined with consolidation of solid and gas phases when force is applied. The key steps in tablet compression are transitional repacking, deformation, fragmentation, bonding, deformation of the solid body, and ejection. Tablet compression physics includes the transmission and distribution of forces, the effect of pressure on powder volume, and interparticle adhesion and cohesion forces.
This document describes the formulation and characterization of nebivolol floating microspheres for gastroretentive drug delivery. Nebivolol is classified as a class II drug with poor solubility and high permeability. Microspheres were prepared using polymers like ethyl cellulose and HPMC via emulsion solvent diffusion method. The microspheres were characterized for particle size, entrapment efficiency, in vitro drug release and buoyancy studies. The results showed the microspheres had prolonged drug release and remained buoyant for over 12 hours, indicating their potential as a gastroretentive drug delivery system.
This document provides information on various molecular pharmaceutics delivery systems including microspheres, niosomes, aquasomes, phytoomes, and electrosomes. It discusses the definition, structure, preparation methods, and applications of microspheres and niosomes. Microspheres are small spherical particles used for sustained drug release that can be produced from natural or synthetic polymers. Niosomes are non-ionic surfactant vesicles similar to liposomes that provide more stability and are used to deliver both hydrophilic and hydrophobic drugs. The document reviews various preparation techniques for these delivery systems.
The document discusses various types of dossiers used in the pharmaceutical industry for regulatory submissions, including Investigation Medicinal Product Dossiers (IMPDs). An IMPD contains information about an investigational drug and is used to support clinical trials. It provides a standardized format for non-clinical and clinical data and should accompany all applications for clinical trials. Other dossiers discussed include Common Technical Documents (CTDs) and country-specific registration dossiers submitted for marketing approval. Effective management of dossier information is important for drug development and regulatory processes.
This document discusses niosomes, which are non-ionic surfactant-based vesicles used for drug delivery. Niosomes have a bilayer structure composed of cholesterol and non-ionic surfactants enclosing an aqueous core. Various preparation methods are described, including ether injection, film hydration, sonication, heating and extrusion. Key factors affecting niosome stability and methods for evaluating niosome characteristics such as size, drug content, entrapment efficiency and in vitro drug release are also summarized. Niosomes provide advantages over other drug carriers such as targeted drug delivery and improved oral bioavailability.
This document discusses gastroretentive drug delivery systems (GRDDS), which are designed to remain in the stomach for an extended period of time in order to allow drugs to be released over a prolonged period. It outlines the need for GRDDS, including for drugs that act locally in the stomach, have a narrow absorption window, or degrade in the colon. Approaches for gastric retention discussed include floating drug delivery systems, mucoadhesive systems, swellable systems, and high density systems. The document also reviews evaluation methods for these different approaches and provides examples of commercial gastroretentive formulations.
The document discusses optimization techniques used in pharmaceutical formulation and processing. It describes how optimization aims to find the best formulation and processing conditions by systematically varying factors and levels. Various experimental designs like factorial designs and response surface methodology are used to optimize multiple variables. Optimization helps develop formulations that meet requirements while allowing efficient mass production.
This document discusses various optimization techniques used in pharmaceutical formulation and processing. It begins by defining optimization and describing how it is applied in the pharmaceutical industry through experimentation and controlling variables. It then covers specific optimization parameters, classic optimization techniques like response surface methodology, and statistical experimental designs. Finally, it discusses modern applied optimization methods like evolutionary operations, simplex method, and Lagrangian method. It provides examples of how these techniques are used and concludes with the role of computers in optimization and some applications.
This document discusses various optimization techniques used in pharmaceutical formulation and processing. It begins with introducing concepts of optimization and defining optimization parameters such as independent and dependent variables. It then describes different experimental design approaches including classical optimization, statistical design of experiments, and various optimization methods like evolutionary operations, simplex method, and Lagrangian method. Specific examples are provided to illustrate full factorial design and simplex optimization approach.
This document provides an overview of gastroretentive drug delivery systems (GRDDS). It discusses the advantages of GRDDS in increasing gastric residence time and absorption of drugs. The key gastroretentive technologies described are floating drug delivery systems that remain buoyant in the stomach, swellable systems that swell and increase in size after administration, and bioadhesive systems that adhere to the stomach wall. Factors affecting GRDDS performance and common evaluation methods are also summarized, including dissolution testing, floating time determination, and water uptake measurement. The document concludes with limitations of GRDDS for certain drug candidates and delivery conditions.
This document discusses gastroretentive drug delivery systems (GRDDS), which aim to prolong the gastric residence time of drugs to allow for increased drug absorption in the stomach or upper gastrointestinal tract. It provides information on appropriate drug candidates for GRDDS, factors affecting gastric retention, advantages and disadvantages of GRDDS, and various approaches to GRDDS design including floating systems, high density systems, swelling systems, and bioadhesive systems. The document also discusses gastric physiology and emptying relevant to GRDDS performance.
This document discusses outsourcing bioavailability and bioequivalence studies to contract research organizations (CROs). It defines key terms like bioavailability, bioequivalence, and CROs. It outlines reasons for outsourcing like reducing costs and improving efficient resources. It describes assessing CRO capabilities in clinical work, bioanalytics, pharmacokinetics, and timelines. It discusses qualifying CROs through due diligence, clinical and bioanalytical site visits, and assessing final report contents and processes like protocol development, clinical conduct, and bioanalytical work. The document provides an overview of outsourcing clinical research to CROs.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...rightmanforbloodline
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
1. REGULATORY REQUIREMENT FOR
APPROVAL OF API, BIOLOGICS, NOVEL
DRUGS AND NDA
1
SUBJECT: REGULATORYAFFAIRS
SUBMITTED BY:
Manoj. R
I s t Sem M. pharm
Dept of pharmaceutics
Nandha college of pharmacy
Erode
2. CONTENT
2
• Approval of :
• API
• Drug Master File OR DMF
• Biologics
• Novel Drug
• Therapies obtaining NDA
3. INTRODUCTION
3
• Active pharmaceutical ingredients (API) are the constituents which
gives medical products are their pharmacological activity. For this
reason the quality and the stability ofAPIs are crucial factors in the
overall quality, safety and efficacy of medicinal products.
• Regulatory guidelines is an organization`s adherence to law`s,
regulations guidelines and specifications relevant to its business.
4. Since APIs are the compounds that actually provide the activity and
effectiveness of all drugs, they are subject to a significant amount of
review during the filing and approval processes.
In order to obtain a marketing authorisation for a drug product the
applicant has to show evidence of efficacy, safety and quality of the
drug product.
To assure this, appropriate documentation on the active substance
including the manufacturing of the active substance has to be
submitted to the competent authority.
Different regions have adopted different procedure for regulatory
filing for API, in U.S it as done as per DMF procedure of FDA while in
Europe it is done byASMF procedure.
4
5. Drug Master File or DMF
5
• Adrug master file is a confidential, detailed document submitted by
Active Pharmaceutical Ingredient (API) manufactures to the U.S Food and
DrugAdministration (FDA).
• It is also called asActive Substance Master File.
• There is no regulatory requirement to file a DMF. However, the document
provides the regulatory authority with confidential, detailed information
about facilities, processes, or articles used in the manufacturing,
processing, packaging, and storing of one or more human drugs.
6. Types of DMFs
6
• Type I :Manufacturing site facilities, operating procedures, and
personnel.
• Type Ⅱ: Drug substance, drug substance intermediate, and uses in
their preparation or drug product.
• Type Ⅲ: Packaging Material.
• Type Ⅳ: Excipient, colorant , flavor, material used in their preparation.
• Type Ⅴ: FDAaccepted reference information.
7. Registration procedure for API in U.S.
• DMFs have no legal or regulatory basis in the United States; however,
they do provide companies a relatively easy and confidential way to
provide confidential information about a process without making it
available to other commercial companies.
• The DMF should contain all of the detailed information expected by
the regulatory authorities so that a DMF reference in an NDA or
ANDA can be used to complete an agency review process. In the
United States there is no approval process for a DMF.
• In fact, DMFs are only examined when referenced in other regulatory
filings, such as an NDA or ANDA; only then is the content of a DMF
reviewed. If requested by FDA headquarters, an FDA inspection may
take place at anAPI manufacturing site after a review of the DMF. 7
8. Registration requirements of DMF
8
• Each DMF submission should contain
A. Transmittal letter
B. Administrative information about the submission
A.Transmittal Letters- The following should be included:
1.OriginalSubmissins
2.Amendments
9. 1. Original submissions
9
i. Identification of submission.
ii. Identification of the applications, if known, that the DMF is intended
to support, including the name and address of each sponsor, applicant,
or holder, and all relevant document numbers
iii. Signature of the holder or the authorized representative.
iv. Typewritten name and title of the signer.
10. 2. Amendments
10
a. Identification of submission:Amendment, the DMF number, type of
DMF, and the subject of the amendment.
b. Adescription of the purpose of submission, e.g. updates, revised
formula, or revised process.
c. Signature of the holder or the authorized representative.
d. Typewritten name and title of the signer.
12. Original Submissions:-
12
1. Names and addresses of the following:
i. DMF holder.
ii. Corporate headquarters.
iii. Manufacturing/processing facility.
iv. Contact for FDAcorrespondence
13. 2. Amendments
13
a) Name of DMF holder.
b) DMF number.
c) Name and address for correspondence.
d) Affected section or page numbers of the DMF.
14. Rules for approval of a novel drug
14
• FDA approval of a drug means that data on the drug’s effects have been
reviewed by CDER, and the drug is determined to provide benefits and
potential risks for the intended population.
15. Biologics / Biological product
15
DEFINITION:
Biological product is a virus, therapeutic serum, toxin,
antitoxin, vaccine, blood component or derivatives, allergenic product or
analogous product , applicable to the prevention ,treatment or cure of a
disease or condition of human beings.
16. Rules for biological product approval
16
• As per FDA, the Blood Establishments registration should follow:-
• All owners or operators of establishments that manufacture blood
products are required to register with the FDA.
• Alist of every blood product manufactured, prepared, or processed for
commercial distribution must also be submitted.
• Products must be registered and listed within 5 days of beginning
operation, and annually between November 15 and December 31.
Blood product listings must be updated every June and December.
17. LAW or ACT
17
• Drug product fall under the Food, Drug and CosmeticAct.
• Biological products fall under the Food Drug and CosmeticAct & Public
Health ServicesAct.
18. Novel Drugs With Its Regulatory Requirements
18
• Novel drugs are often innovative products that serve previously unmate
medical needs and significantly help to advance patient treatments.
• Noval drugs can represent important new therapies for advancing patient
care.
• In 2017 CDER gave approval to many noval drugs includes as ;
Dupixent : to treat adult with moderate-to severe eczema (atopic
dermatitis).
19. Rules for approval of a novel drug:
19
• FDAapproval of a drug means that data on the drug’s effects have been
reviewed by CDER.
• The drug is determined to provide benefits that outweigh its known and
potential risks for the intended population.
• These approaches can includes more interaction between CDER staff
and drug developers, and shortened timelines for review of application.
• The drug approval process takes place within a structured framework
that includes:
20. Analysis of the target condition and available treatments-
• FDA reviewers analyse the condition or illness for which the drug is
intended and evaluate the current treatment landscape, which provide
the context for weighing the drug’s risks and benefits.
Assessment of benefits and risks from clinical data—
• FDAreviewers evaluate clinical benefit and risk information
submitted by the drug maker,
Strategies for managing risks—
• All drugs have risks. Risk management strategies include on FDA-
approved drug label, which clearly describes the drug’s benefits and 20
risks, and how the risks can be detected and managed.
21. Newer Approach- Faster Testing & Approval
21
• The mechanisms speed up the approval process, and apply a degree of
flexibility with respect to the evidence requirements for the approval of
certain medicines.
• In the U.S., accelerated pathways (APs) include Fast Track (FT),
Breakthrough Therapy Designation (BTD),AcceleratedApproval
(AA), and Priority Review (PR).
22. Fast Track (FT):
22
• Fast track is a process designed to facilitate the development of drugs
to treat serious or prevent a condition.
• If there are available therapies, a fast track drug must show some
advantage over available therapy.
• Avoiding serious side effects of an available therapy
• Improving the diagnosis of a serious condition.
23. Breakthrough Therapy (BT):
• Breakthrough Therapy designation, clinically significant endpoint
generally refers to an endpoint that measures an effect on irreversible
morbidity or mortality (IMM) or on symptoms that represent serious
consequences of the disease.
• Aclinically significant endpoint can also refer to findings that suggest
an effect on IMM or serious symptoms.
• An effect on an established surrogate endpoint.
• Asignificantly improved safety profile compared to available therapy
(eg :- less dose-limiting toxicity for an oncology agent) 23
24. Priority Review (PR):
24
• Prior to approval, each drug marketed in the United States must go through a
detailed FDAreview process.
• Under the Prescription Drug User Act (PDUFA), FDA agreed to specific
goals for improving the drug review time and created a two-tiered system of
review times – Standard Review and Priority Review.
• APriority Review designation means FDA’s goal is to take action on an
application within 6 months (compared to 10 months under standard
review).
25. Accelerated Approval (AA):
25
• In 2012, Congress passed the Food and DrugAdministration Safety
InnovationsAct (FDASIA).
• These accelerated approval endpoints may includes ones that shows
benefits over a shorter duration of treatments.
• Accelerated approval brings drug that can provides important advances
to patients sooner than with traditional approvals.
26. NEW DRUG APPROVALS
26
DEFINITION :-
• It is a regulatory mechanism that is designed to give Food and Drug
Administration (FDA)sufficient information to make a meaningful
evaluation of a New Drug.
• New DrugApplication is the vehicle in the United States through which
the drug sponsors formally propose that the FDA approve a new
pharmaceutical for sale and marketing.
27. OBJECTIVES
27
Upon the completion of this presentation student gets to learn
To know the approval process of NDA
Drug development process
concepts of innovator and generic drugs
28. CLINICAL TRIALS :-
28
10-15 years from lab to US patients.
Only 1 in 5000 compounds make it to the human testing.
Only 1 in 5 tested in humans is approved.
Testing phases in Humans
a) Discovery
b) Development
c) Clinical Studies
d) Medicine approved
29. HISTORY
29
When the federal food, drug and cosmetic act 1938 was passed, a
new era of drug product development began.
The act required the assurance of safety and stated minimum
requirements for manufacturing and quality control.
It provided only 60 days for review by FDAbefore the distribution of
any new drug product.
30. GOAL :-
30
Safety and effectiveness of a drug in its proposed use.
Whether the drug proposed labelling (package insert) is appropriate.
Methods used in manufacturing the drug and the controls used to
maintain the drugs quality are adequate to preserve the drugs identity,
strength , quality and purity.
The benefits of the drug outweigh the risks.